## **Raymond L Rosales**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/663645/publications.pdf Version: 2024-02-01

236925 243625 98 2,256 25 44 citations h-index g-index papers 111 111 111 2114 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Novel <i>PINK1</i> mutations in earlyâ€onset parkinsonism. Annals of Neurology, 2004, 56, 424-427.	5.3	247
2	Dissecting the Causal Mechanism of X-Linked Dystonia-Parkinsonism by Integrating Genome and Transcriptome Assembly. Cell, 2018, 172, 897-909.e21.	28.9	163
3	The Unique Phenomenology of Sex-Linked Dystonia Parkinsonism (XDP, DYT3, "Lubagâ€). International Journal of Neuroscience, 2011, 121, 3-11.	1.6	130
4	Parkinson's disease in the Western Pacific Region. Lancet Neurology, The, 2019, 18, 865-879.	10.2	116
5	Botulinum Toxin Injection for Hypertonicity of the Upper Extremity Within 12 Weeks After Stroke. Neurorehabilitation and Neural Repair, 2012, 26, 812-821.	2.9	106
6	Genetic mapping of ?Lubag? (X-linked dystonia-parkinsonism) in a filipino kindred to the pericentromeric region of the X chromosome. Annals of Neurology, 1991, 29, 124-131.	5.3	89
7	New insights into the genetics of X-linked dystonia-parkinsonism (XDP, DYT3). European Journal of Human Genetics, 2015, 23, 1334-1340.	2.8	73
8	Mutations in <i>GNAL</i> . JAMA Neurology, 2014, 71, 490.	9.0	70
9	A hexanucleotide repeat modifies expressivity of Xâ€linked dystonia parkinsonism. Annals of Neurology, 2019, 85, 812-822.	5.3	67
10	Botulinum toxin as early intervention for spasticity after stroke or non-progressive brain lesion: A meta-analysis. Journal of the Neurological Sciences, 2016, 371, 6-14.	0.6	65
11	Defining spasticity: a new approach considering current movement disorders terminology and botulinum toxin therapy. Journal of Neurology, 2018, 265, 856-862.	3.6	51
12	Neuroanatomical changes extend beyond striatal atrophy in X-linked dystonia parkinsonism. Parkinsonism and Related Disorders, 2016, 31, 91-97.	2.2	42
13	Basal ganglia and cerebellar pathology in X-linked dystonia-parkinsonism. Brain, 2018, 141, 2995-3008.	7.6	41
14	Evidence of TAF1 dysfunction in peripheral models of X-linked dystonia-parkinsonism. Cellular and Molecular Life Sciences, 2016, 73, 3205-3215.	5.4	37
15	Striosomal dysfunction affects behavioral adaptation but not impulsivity—Evidence from Xâ€linked dystoniaâ€parkinsonism. Movement Disorders, 2017, 32, 576-584.	3.9	37
16	Consensus guidelines for botulinum toxin therapy: general algorithms and dosing tables for dystonia and spasticity. Journal of Neural Transmission, 2021, 128, 321-335.	2.8	37
17	Association of Pallidal Neurostimulation and Outcome Predictors With X-linked Dystonia Parkinsonism. JAMA Neurology, 2019, 76, 211.	9.0	36
18	Genome editing in induced pluripotent stem cells rescues <i>TAF1</i> levels in Xâ€linked dystoniaâ€parkinsonism. Movement Disorders, 2018, 33, 1108-1118.	3.9	35

#	Article	IF	CITATIONS
19	Identifying genetic modifiers of age-associated penetrance in X-linked dystonia-parkinsonism. Nature Communications, 2021, 12, 3216.	12.8	34
20	X-Linked Dystonia Parkinsonism: Clinical Phenotype, Genetics and Therapeutics. Journal of Movement Disorders, 2010, 3, 32-38.	1.3	33
21	The Broadening Application of Chemodenervation in X-Linked Dystonia-Parkinsonism (Part II): An Open-Label Experience With Botulinum Toxin-A (Dysport®) Injections for Oromandibular, Lingual, and Truncal-Axial Dystonias. International Journal of Neuroscience, 2011, 121, 44-56.	1.6	32
22	Botulinum toxin therapy for treatment of spasticity in multiple sclerosis: review and recommendations of the IAB-Interdisciplinary Working Group for Movement Disorders task force. Journal of Neurology, 2017, 264, 112-120.	3.6	32
23	Strategies for treatment of dystonia. Journal of Neural Transmission, 2016, 123, 251-258.	2.8	31
24	Early AbobotulinumtoxinA (Dysport®) in Post-Stroke Adult Upper Limb Spasticity: ONTIME Pilot Study. Toxins, 2018, 10, 253.	3.4	31
25	Perceptions of Painful Diabetic Peripheral Neuropathy in South-East Asia: Results from Patient and Physician Surveys. Advances in Therapy, 2017, 34, 1426-1437.	2.9	29
26	The Basal Ganglia Striosomes Affect the Modulation of Conflicts by Subliminal Information—Evidence from X-Linked Dystonia Parkinsonism. Cerebral Cortex, 2018, 28, 2243-2252.	2.9	29
27	Lewy body disease or diseases with Lewy bodies?. Npj Parkinson's Disease, 2022, 8, 3.	5.3	26
28	Delivering patient-centered care in Parkinson's disease: Challenges and consensus from an international panel. Parkinsonism and Related Disorders, 2020, 72, 82-87.	2.2	25
29	Woman With X-Linked Recessive Dystonia-Parkinsonism. JAMA Neurology, 2014, 71, 1177.	9.0	24
30	Increased insula-putamen connectivity in X-linked dystonia-parkinsonism. Neurolmage: Clinical, 2018, 17, 835-846.	2.7	23
31	Imaging gradual neurodegeneration in a basal ganglia model disease. Annals of Neurology, 2019, 86, 517-526.	5.3	23
32	Long-term outcomes of pallidal deep brain stimulation in X-linked dystonia parkinsonism (XDP): Up to 84 months follow-up and review of literature. Parkinsonism and Related Disorders, 2019, 60, 81-86.	2.2	23
33	Expanding Data Collection for the <scp>MDSGene</scp> Database: Xâ€linked Dystoniaâ€Parkinsonism as Use Case Example. Movement Disorders, 2020, 35, 1933-1938.	3.9	23
34	Non-motor predictors of 36-month quality of life after subthalamic stimulation in Parkinson disease. Npj Parkinson's Disease, 2021, 7, 48.	5.3	23
35	What's the "catch―in upper-limb post-stroke spasticity: Expanding the role of botulinum toxin applications. Parkinsonism and Related Disorders, 2011, 17, S3-S10.	2.2	22
36	Cross-sectional analysis of the Parkinson's disease Non-motor International Longitudinal Study baseline non-motor characteristics, geographical distribution and impact on quality of life. Scientific Reports, 2021, 11, 9611.	3.3	21

#	Article	IF	CITATIONS
37	Nonmotor Symptoms in Dystonia. International Review of Neurobiology, 2017, 134, 1335-1371.	2.0	20
38	Validation of the XDP–MDSP rating scale for the evaluation of patients with X-linked dystonia-parkinsonism. Npj Parkinson's Disease, 2017, 3, 24.	5.3	18
39	Brain Regional Differences in Hexanucleotide Repeat Length in X-Linked Dystonia-Parkinsonism Using Nanopore Sequencing. Neurology: Genetics, 2021, 7, e608.	1.9	18
40	Pain in cervical dystonia: mechanisms, assessment and treatment. Expert Review of Neurotherapeutics, 2021, 21, 1125-1134.	2.8	18
41	Botulinum neurotoxin injections for muscle-based (dystonia and spasticity) and non-muscle-based (neuropathic pain) pain disorders: a meta-analytic study. Journal of Neural Transmission, 2020, 127, 935-951.	2.8	17
42	The Broadening Application of Chemodenervation in X-Linked Dystonia-Parkinsonism (Part I): Muscle Afferent Block Versus Botulinum Toxin-A in Cervical and Limb Dystonias. International Journal of Neuroscience, 2011, 121, 35-43.	1.6	16
43	Botulinum toxin therapy of dystonia. Journal of Neural Transmission, 2021, 128, 531-537.	2.8	14
44	Uncovering the Mystery From the Philippine Island of Panay. International Journal of Neuroscience, 2011, 121, 1-2.	1.6	13
45	RAB39B mutations are a rare finding in Parkinson disease patients. Parkinsonism and Related Disorders, 2016, 23, 116-117.	2.2	13
46	Botulinum neurotoxin a therapy efficacy and safety for oromandibular dystonia: a meta-analysis. Journal of Neural Transmission, 2019, 126, 141-148.	2.8	13
47	Sonographic alteration of substantia nigra is related to parkinsonism-predominant course of X-linked dystonia-parkinsonism. Parkinsonism and Related Disorders, 2017, 37, 43-49.	2.2	12
48	Dysfunctions in striatal microstructure can enhance perceptual decision making through deficits in predictive coding. Brain Structure and Function, 2017, 222, 3807-3817.	2.3	12
49	Eye movement deficits in X-linked dystonia-parkinsonism are related to striatal degeneration. Parkinsonism and Related Disorders, 2019, 61, 170-178.	2.2	12
50	Neurophysiological fingerprints of Xâ€linked dystoniaâ€parkinsonism: A model basal ganglia disease. Movement Disorders, 2015, 30, 873-875.	3.9	11
51	How Can We Improve Current Practice in Spastic Paresis?. European Neurological Review, 2016, 11, 79.	0.5	11
52	Mosaic divergent repeat interruptions in XDP influence repeat stability and disease onset. Brain, 2023, 146, 1075-1082.	7.6	10
53	Cilostazol: A Pilot Study on Safety and Clinical Efficacy in Neuropathies of Diabetes Mellitus Type 2 (ASCEND). Angiology, 2011, 62, 625-635.	1.8	9
54	Untreated Depressive Symptoms Among Cognitively-Intact, Community Dwelling Filipino Patients With Parkinson Disease. International Journal of Neuroscience, 2011, 121, 137-141.	1.6	9

#	Article	IF	CITATIONS
55	Elucidating Hexanucleotide Repeat Number and Methylation within the X-Linked Dystonia-Parkinsonism (XDP)-Related SVA Retrotransposon in TAF1 with Nanopore Sequencing. Genes, 2022, 13, 126.	2.4	9
56	A Case Report on Dyskinesia Following Rivastigmine Patch 13.3 mg/24 hours for Alzheimer's Disease. Medicine (United States), 2015, 94, e1364.	1.0	8
57	<scp>DNA</scp> Methylation as a Potential Molecular Mechanism in Xâ€linked Dystoniaâ€Parkinsonism. Movement Disorders, 2020, 35, 2220-2229.	3.9	7
58	Clinical practice with steroid therapy for Duchenne muscular dystrophy: An expert survey in Asia and Oceania. Brain and Development, 2020, 42, 277-288.	1.1	7
59	X-linked dystonia Parkinsonism: crossing a new threshold. Journal of Neural Transmission, 2021, 128, 567-573.	2.8	7
60	First Report of a Filipino with Mohrâ€Tranebjaerg Syndrome. Movement Disorders Clinical Practice, 2015, 2, 417-419.	1.5	6
61	Transcriptional Alterations in X-Linked Dystonia–Parkinsonism Caused by the SVA Retrotransposon. International Journal of Molecular Sciences, 2022, 23, 2231.	4.1	6
62	Botulinum toxin therapy as an early intervention for post-stroke spasticity: Beyond a functional viewpoint. Journal of the Neurological Sciences, 2017, 382, 187-188.	0.6	5
63	Treatment of oromandibular dystonia using botulinum toxin injections – Case series and illustrative muscle targeting. Basal Ganglia, 2018, 13, 7-16.	0.3	5
64	Contemporary clinical neurophysiology applications in dystonia. Journal of Neural Transmission, 2021, 128, 509-519.	2.8	4
65	The Occurrence of Fatigue in Independent and Clinically Stable Filipino Patients with Idiopathic Parkinson's Disease. Journal of Movement Disorders, 2009, 2, 18-21.	1.3	4
66	Mental Dysfunctions in Dystonia-Plus Syndromes. Journal of Parkinson's Disease, 2014, 4, 161-167.	2.8	3
67	Effect of early use of AbobotulinumtoxinA after stroke on spasticity progression: Protocol for a randomised controlled pilot study in adult subjects with moderate to severe upper limb spasticity (ONTIME pilot). Contemporary Clinical Trials Communications, 2017, 6, 9-16.	1.1	3
68	Temperature sensation in Parkinson's disease measured by quantitative sensory testing: a single-center, case-control study. International Journal of Neuroscience, 2023, 133, 834-839.	1.6	2
69	Indirect Central Nervous System Effects of Botulinum Toxin. , 0, , 106-110.		1
70	A Cross-Cultural Validation of the Filipino and Hiligaynon Versions of the Parts IIIB (Non-Motor) Tj ETQq0 0 0 rgBT Clinical Parkinsonism & Related Disorders, 2021, 5, 100100.	/Overlock 0.9	10 Tf 50 14 1
71	Botulinum Toxin Injection for Pain in Muscle Spasm and Visceromotor Disorders: A Meta-Analytic Study. Journal of Medicine University of Santo Tomas, 2017, 1, 69-78.	0.1	1
72	Prevalence and Predisposing Factors of Parkinson Disease: A Community-Based Study In Barangay Mangilag Sur, Candelaria, Quezon: A Research Protocol. Journal of Medicine University of Santo Tomas, 2017, 1, 109-119.	0.1	1

#	Article	IF	CITATIONS
73	Calpainopathy (Leyden-Mobius Limb-Girdle Muscular Dystrophy Type 2A Phenotype) and Dysferlinopathy (Miyoshi Distal Myopathy Limb-Girdle Muscular Dystrophy Type 2B Phenotype) of Preadolescent Onset: Case Reports of Two Male Filipinos. Cureus, 2022, 14, e21353.	0.5	1
74	171. Botulinum neurotoxin injections for oromandibular dystonias. Toxicon, 2015, 93, S53.	1.6	0
75	45. An international, prospective cohort to document the effectiveness of 1 cycle of BoNT/A based on attainment ofÂindividual person-centered goals in adult subjects suffering from upper limb spasticity following stroke (ULIS II): subanalysis of the South Asian group of spasticity patients. Toxicon, 2015, 93. S15-S16.	1.6	0
76	Baseline characteristics of patients from a pilot study to assess the effect of early use of abobotulinumtoxinA (Dysport®) after stroke on spasticity progression. Toxicon, 2016, 123, S71.	1.6	0
77	Botulinum neurotoxin for lip and tongue dystonia: "Drooling along the way― Toxicon, 2018, 156, S98.	1.6	0
78	Untwisting dystonia: stepping-up genetics, shifting pathophysiology, and strategizing care. Journal of Neural Transmission, 2021, 128, 393-394.	2.8	0
79	Dystonia: The Syndrome, Its Term, Concept and Their Evolution. , 2015, , 3-12.		0
80	Dystonia–Parkinsonism Syndromes. , 2015, , 75-88.		0
81	Successfully Treated Waldenstrom Macroglobulinemia with Nine-year Follow-up: Case Report and Review of Neurologic Manifestations. Journal of Neurological Disorders, 2016, 4, .	0.1	Ο
82	Post-Varicella Acute In ammatory Demyelinating Polyradiculoneuropathy in a 51-year old Filipino Male: A Case Report. Journal of Medicine University of Santo Tomas, 2017, 1, 93-97.	0.1	0
83	Recurrent Bifacial Neuropathy in a Case of Steroid Responsive Neurosarcoidosis: A Case Report. Journal of Medicine University of Santo Tomas, 2017, 1, 87-92.	0.1	Ο
84	Ostinato Rigore in Research - Message from The Editor-In Chief. Journal of Medicine University of Santo Tomas, 2018, 2, 120-120.	0.1	0
85	Acute Ischemic Stroke in a Filipino with Parkinsonian Fahr's Disease: A Case Report. Journal of Medicine University of Santo Tomas, 2018, 2, 220-223.	0.1	Ο
86	Filipino Version of Penn Facial Pain Scale: Phase 1 Validation Study. Journal of Medicine University of Santo Tomas, 2018, 2, .	0.1	0
87	Time to Ride the Wave of Precision Medicine. Journal of Medicine University of Santo Tomas, 2019, 3, 245-247.	0.1	0
88	Mileage in Research Collaboration. Journal of Medicine University of Santo Tomas, 2019, 3, .	0.1	0
89	Preparing for the Expected. Journal of Medicine University of Santo Tomas, 2020, 4, 477-478.	0.1	0
90	Scientific Publishing: Vital for Public Health and Authors. Journal of Medicine University of Santo Tomas, 2020, 4, 393-393.	0.1	0

#	Article	IF	CITATIONS
91	A mixed-ethnicity myoclonus-dystonia patient with a novel SGCE nonsense mutation: a case report. BMC Neurology, 2022, 22, 11.	1.8	0
92	Physician-Scientist, Academician and Published Research Author. Journal of Medicine University of Santo Tomas, 2021, 5, 670-670.	0.1	0
93	Constrictive Entrapment Neuropathies of a Limb Secondary to Restraint Strapping: A Case Report. Journal of Medicine University of Santo Tomas, 2021, 5, 798-801.	0.1	0
94	Viewpoint: Physician as a Clinician, Researcher, and Academician. Journal of Medicine University of Santo Tomas, 2021, 5, 671-674.	0.1	0
95	Botulinum Neurotoxin A for Hand Tremors in Parkinson's Disease: A Meta-Analytic Study. Journal of Medicine University of Santo Tomas, 2022, 6, 814-822.	0.1	0
96	No Pain No Gain - Quest for Academic and Research Excellence. Journal of Medicine University of Santo Tomas, 2022, 6, 813-813.	0.1	0
97	Reply: Matters Arising †Lewy body disease or diseases with Lewy bodies?'. Npj Parkinson's Disease, 2022, 8, .	5.3	0
98	Efficacy and safety of apomorphine pump infusion in Filipino patients insufficiently controlled on oral anti-Parkinson medications: an open-label, pilot study. International Journal of Neuroscience, 2024, 134, 131-136.	1.6	0

7